Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment

Novartis

Status: Completed

Conditions: Psoriasis (PsO); Psoriatic Arthritis (PsA)

Study type: Observational

Funder types: Industry

Identifiers

NCT06666114

CAIN457FBR04

Details and patient eligibility

About

This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites. At least 12 months of patient data was verified, comprising at least 6 months (pre-period) and 6 months (post-period) after secukinumab initiation (index date). All data extracted from patient charts was entered into an electronic case report form (eCRF), specifically designed to capture all variables needed for the study data analysis.

Enrollment: 232 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients aged ≥18 years at index date.
• Patients with PsO diagnosed with PsA (concomitant or sequentially), either by a rheumatologist or dermatologist, at least 6 months prior to initiation of secukinumab treatment.
• Continuously treated with secukinumab for at least 24 weeks (6 months) after index date.
• Medical history available from at least the one-year study period (at least 6 months previous to the start of secukinumab treatment and at least 6 months after).

Exclusion criteria

• Patients who interrupted secukinumab treatment for 3 or more months during the 6-month period (post-period) for any cause.
• Patients known to be participating in an interventional study at any point of the one-year study period.